Abstract: In one embodiment, a domain controller (a) quarantines unknown devices at a first quarantine point at a first layer of a multi-layer communication model; (b) communicates with a domain name system (DNS) service to self-allocate and register a domain name with the DNS service; (c) receives a provisioning request for a first device via an access point, wherein the access point comprises a second quarantine point at a second layer of the multi-level communication model; (d) verifies a device type of the first device with the DNS service; and (e) responsive to that verification, provisions the first device into the domain. The domain controller may also send a provisioning response to the access point to enable the first device to be removed from the second quarantine point, to enable the first device to communicate with the domain controller. Other embodiments are described and claimed.

Abstract: In one embodiment, a domain controller includes a quarantine logic to quarantine unknown devices from unrestricted network access. The quarantine logic comprises a first quarantine point at a first layer of a multi-layer communication model. The domain controller also includes: a first logic to communicate with a domain name system (DNS) service to self-allocate and register a domain name with the DNS service, the domain name associated with a domain to be managed by the domain controller; a second logic to manage a group of devices of the domain; and a third logic to receive a provisioning request for a first device via an access point that comprises a second quarantine point at a second layer of the multi-level communication model. The second layer is a lower layer than the first layer, and the second quarantine point is more restrictive than the first. Other embodiments are described and claimed.

Abstract: In one embodiment, a domain controller includes a quarantine logic to quarantine unknown devices from unrestricted network access. The quarantine logic comprises a first quarantine point at a first layer of a multi-layer communication model. The domain controller also includes: a first logic to communicate with a domain name system (DNS) service to self-allocate and register a domain name with the DNS service, the domain name associated with a domain to be managed by the domain controller; a second logic to manage a group of devices of the domain; and a third logic to receive a provisioning request for a first device via an access point that comprises a second quarantine point at a second layer of the multi-level communication model. The second layer is a lower layer than the first layer, and the second quarantine point is more restrictive than the first. Other embodiments are described and claimed.

Abstract: In one embodiment, a domain controller includes a quarantine logic to quarantine unknown devices from unrestricted network access. The quarantine logic comprises a first quarantine point at a first layer of a multi-layer communication model. The domain controller also includes: a first logic to communicate with a domain name system (DNS) service to self-allocate and register a domain name with the DNS service, the domain name associated with a domain to be managed by the domain controller; a second logic to manage a group of devices of the domain; and a third logic to receive a provisioning request for a first device via an access point that comprises a second quarantine point at a second layer of the multi-level communication model. The second layer is a lower layer than the first layer, and the second quarantine point is more restrictive than the first. Other embodiments are described and claimed.

Abstract: In one embodiment, a domain controller includes: a quarantine logic to quarantine unknown devices from unrestricted network access, the quarantine logic comprising a first quarantine point at a first layer of a multi-layer communication model; a first logic to communicate with a domain name system (DNS) service to self-allocate and register a domain name with the DNS service, the domain name associated with a domain to be managed by the domain controller; a second logic to manage a group of devices of the domain; and a third logic to receive a provisioning request for a first device via an access point, wherein the access point comprises a second quarantine point at a second layer of the multi-level communication model. Other embodiments are described and claimed.

Abstract: Technologies for trusted device on-boarding include a first computing device to generate a first public Diffie-Hellman key based on a private Diffie-Hellman key and a first unique identifier of the first computing device. The first unique identifier is retrieved from secure memory of the first computing device. The first computing device transmits the first public Diffie-Hellman key to a second computing device and receives, from the second computing device, a second public Diffie-Hellman key of the second computing device. The second public Diffie-Hellman key incorporates a second unique identifier of the second computing device. Further, the first computing device removes a contribution of the second unique identifier from the second public Diffie-Hellman key to generate a modified public Diffie-Hellman key and generates a shared Diffie-Hellman key based on the modified public Diffie-Hellman key and the private Diffie-Hellman key of the first computing device.

Abstract: In one embodiment, a domain controller includes: a quarantine logic to quarantine unknown devices from unrestricted network access, the quarantine logic comprising a first quarantine point at a first layer of a multi-layer communication model; a first logic to communicate with a domain name system (DNS) service to self-allocate and register a domain name with the DNS service, the domain name associated with a domain to be managed by the domain controller; a second logic to manage a group of devices of the domain; and a third logic to receive a provisioning request for a first device via an access point, wherein the access point comprises a second quarantine point at a second layer of the multi-level communication model. Other embodiments are described and claimed.

Abstract: Technologies for trusted device on-boarding include a first computing device to generate a first public Diffie-Hellman key based on a private Diffie-Hellman key and a first unique identifier of the first computing device. The first unique identifier is retrieved from secure memory of the first computing device. The first computing device transmits the first public Diffie-Hellman key to a second computing device and receives, from the second computing device, a second public Diffie-Hellman key of the second computing device. The second public Diffie-Hellman key incorporates a second unique identifier of the second computing device. Further, the first computing device removes a contribution of the second unique identifier from the second public Diffie-Hellman key to generate a modified public Diffie-Hellman key and generates a shared Diffie-Hellman key based on the modified public Diffie-Hellman key and the private Diffie-Hellman key of the first computing device.

Abstract: Nucleic acid sequences and methods are provided for producing plants and seeds having altered tocopherol content and compositions. The methods find particular use in increasing the tocopherol levels in plants, and in providing desirable tocopherol compositions in a host plant cell.

Abstract: Nucleic acid sequences and methods are provided for producing plants and seeds having altered tocopherol content and compositions. The methods find particular use in increasing the tocopherol levels in plants, and in providing desirable tocopherol compositions in a host plant cell.

Abstract: Nucleic acid sequences and methods are provided for producing plants and seeds having altered tocopherol content and compositions. The methods find particular use in increasing the tocopherol levels in plants, and in providing desirable tocopherol compositions in a host plant cell.

Abstract: This invention relates to a nucleotide array containing polynucleotide probes complementary to, or fragments of, Cynomolgus monkey genes, and the use of such a nucleotide array to characterize the biological effects, including the actions, targets, and toxicities, of therapeutic agents in primates, e.g., a human, a Cynomolgus monkey, or a Rhesus monkey, in particular a nucleotide array to be used in identifying the toxicities of therapeutic agents administered to a non-human primate, e.g., a Cynomolgus monkey or a Rhesus monkey.

Abstract: The subject invention concerns peptide molecules that specifically inhibit the enzymatic function of tyrosine kinases, including the JAK and EGF receptor (EGFR) family of kinases, to autophosphorylate, i.e., to transfer a phosphate group from ATP to an amino acid in the kinase. Phosphorylation of proteins is the most fundamental method for signal transduction among proteins in a cell. Inhibition of tyrosine kinase autophosphorylation activities inhibits the enzyme's signaling and shuts down the functioning pathways originating from the enzyme. The JAK2 and EGFR tyrosine kinases are involved in both inflammatory disorders and cancer. In these disorders, the tyrosine kinases can often be activated in an uncontrolled fashion. The subject application also concerns antibodies that bind to a tyrosine kinase autophosphorylation site.

Abstract: Nucleic acid sequences and methods are provided for producing plants and seeds having altered tocopherol content and compositions. The methods find particular use in increasing the tocopherol levels in plants, and in providing desirable tocopherol compositions in a host plant cell.

Abstract: The subject invention concerns peptide molecules that specifically inhibit the enzymatic function of tyrosine kinases, including the JAK and EGF receptor (EGFR) family of kinases, to autophosphorylate, i.e., to transfer a phosphate group from ATP to an amino acid in the kinase. Phosphorylation of proteins is the most fundamental method for signal transduction among proteins in a cell. Inhibition of tyrosine kinase autophosphorylation activities inhibits the enzyme's signaling and shuts down the functioning pathways originating from the enzyme. The JAK2 and EGFR tyrosine kinases are involved in both inflammatory disorders and cancer. In these disorders, the tyrosine kinases can often be activated in an uncontrolled fashion. The subject application also concerns antibodies that bind to a tyrosine kinase autophosphorylation site.

Abstract: An improved process for the commercial production of malononitrile by the dehydration of cyanoacetamide employs cyanuric chloride in the presence of a catalytic amount of N,N-dimethylformamide and in a polar solvent that is removed by vacuum distillation at a temperature below 100° C. The N,N-dimethylformamide is added in a molar ratio of 0.16 moles for each mole of cyanoacetamide present in the starting solution.

Abstract: C3-12 alkyl, substituted alkyl, alkenyl and cycloalkyl cyanoacetates are prepared by an efficient and simplified one-step process in which a small molar excess of the corresponding alcohol, i.e., C3-12 alkyl, substituted alkyl, alkenyl or cycloalkenyl alcohol is reacted with crystalline cyanoacetic acid, or a concentrated aqueous solution of cyanoacetic acid, in the presence of an acid catalyst, such as, for example, methanesulfonic acid, p-toluenesulfonic acid, sulfuric acid and phosphoric acid at a temperature in the range of from about 60° C. to about 150° C., in accordance with the following reaction: CNCH2COOH+R—OH→(cat)CNCH2COOR+H2O  (I) where R is a C3-12 alkyl, substituted alkyl, alkenyl or cycloalkyl.

Abstract: The present invention relates to a general synthesis for producing secondaryalkoxy-1-alkenes in commercial quantities in good yields by reacting cyclic and acyclic ketones and the corresponding alcohol with a secondary alkyl orthoformate ester in the presence of an acid catalyst, a Lewis acid, ferric chloride being preferred, and recovering the produce as a liquid of high purity.

Abstract: The invention describes a method of reducing the cytotoxicity of interferon-alpha by making defined amino acid substitutions in the N-terminal portion of the polypeptide sequence. Also described are human interferon-alpha analogs with low cytotoxicity, and therapeutic applications of the low toxicity interferon-alpha analogs.

Abstract: Alkyl, aralkyl or aryl cyanoformate esters having from one to 20 carbon atoms are prepared by anhydrously reacting stoichiometric amounts of the corresponding alkyl, aralkyl or aryl haloformate and an organosilyl nitrile in the presence of a catalytic amount of a tertiary amine base, preferably 1,4-diazabicyclo?2.2.2!octane, in the absence or presence of an inert solvent. The reaction is conducted at a temperature of from about -30.degree. C. to 70.degree. C., preferably at from about 5.degree. C. to 30.degree. C.